These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18365201)

  • 61. Heparin derivatives as angiogenesis inhibitors.
    Presta M; Leali D; Stabile H; Ronca R; Camozzi M; Coco L; Moroni E; Liekens S; Rusnati M
    Curr Pharm Des; 2003; 9(7):553-66. PubMed ID: 12570803
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999).
    d'Onofrio A; Gandolfi A
    Math Biosci; 2004 Oct; 191(2):159-84. PubMed ID: 15363652
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A mathematical model for capillary formation and development in tumor angiogenesis: a review.
    Pamuk S
    Chemotherapy; 2006; 52(1):35-7. PubMed ID: 16340197
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Endogenous angiogenesis inhibitors as therapeutic agents: historical perspective and future direction.
    Dhanabal M; Sethuraman N
    Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):223-36. PubMed ID: 18221039
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Stochastic modelling of tumour-induced angiogenesis.
    Capasso V; Morale D
    J Math Biol; 2009 Jan; 58(1-2):219-33. PubMed ID: 18542963
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Are tumours angiogenesis-dependent?
    Verheul HM; Voest EE; Schlingemann RO
    J Pathol; 2004 Jan; 202(1):5-13. PubMed ID: 14694516
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Angiogenesis inhibitors in cancer therapy.
    Dredge K; Dalgleish AG; Marriott JB
    Curr Opin Investig Drugs; 2003 Jun; 4(6):667-74. PubMed ID: 12901224
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Inhibition of vascularization in tumor growth.
    Scalerandi M; Sansone BC
    Phys Rev Lett; 2002 Nov; 89(21):218101. PubMed ID: 12443451
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A two-dimensional model for studying tumor angiogenesis inhibitors.
    Gao P; Yang JL; Wang H; Wu XD; Jiao SC
    Cancer Invest; 2013 Jun; 31(5):346-58. PubMed ID: 23641911
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Angiogenesis and hematological malignancies.
    Lim ST; Levine AM
    Hematology; 2005 Feb; 10(1):11-24. PubMed ID: 16019441
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
    Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging.
    Li WW
    Acad Radiol; 2000 Oct; 7(10):800-11. PubMed ID: 11048878
    [No Abstract]   [Full Text] [Related]  

  • 74. Role of angiogenesis in tumor growth and metastasis.
    Folkman J
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):15-8. PubMed ID: 12516034
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.
    Tammela T; Zarkada G; Wallgard E; Murtomäki A; Suchting S; Wirzenius M; Waltari M; Hellström M; Schomber T; Peltonen R; Freitas C; Duarte A; Isoniemi H; Laakkonen P; Christofori G; Ylä-Herttuala S; Shibuya M; Pytowski B; Eichmann A; Betsholtz C; Alitalo K
    Nature; 2008 Jul; 454(7204):656-60. PubMed ID: 18594512
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
    Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
    Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacological regulation of platelet factors that influence tumor angiogenesis.
    Yan M; Lesyk G; Radziwon-Balicka A; Jurasz P
    Semin Oncol; 2014 Jun; 41(3):370-7. PubMed ID: 25023352
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Tumor angiogenesis and therapy.
    Cao Y
    Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S340-3. PubMed ID: 16507405
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Emergence of taxis and synergy in angiogenesis.
    Capogrosso Sansone B; Scalerandi M; Condat CA
    Phys Rev Lett; 2001 Sep; 87(12):128102. PubMed ID: 11580561
    [TBL] [Abstract][Full Text] [Related]  

  • 80. PE, a new sulfated saponin from sea cucumber, exhibits anti-angiogenic and anti-tumor activities in vitro and in vivo.
    Tian F; Zhang X; Tong Y; Yi Y; Zhang S; Li L; Sun P; Lin L; Ding J
    Cancer Biol Ther; 2005 Aug; 4(8):874-82. PubMed ID: 16082187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.